A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting.

@article{Whitehall2009AMB,
  title={A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting.},
  author={Vicki L. J. Whitehall and Kayla L Tran and Aarti Umapathy and Fabienne Grieu and Chelsee Hewitt and T Evans and Tuty Muliana Ismail and Wei Qi Li and Peter V Collins and Paul F Ravetto and Barbara Leggett and Manuel Salto-Tellez and Richie Soong and Stephen Fox and Rodney J. Scott and Alexander Dobrovic and Barry J Iacopetta},
  journal={The Journal of molecular diagnostics : JMD},
  year={2009},
  volume={11 6},
  pages={543-52}
}
Evidence that activating mutations of the KRAS oncogene abolish the response to anti-epidermal growth factor receptor therapy has revolutionized the treatment of advanced colorectal cancer. This has resulted in the urgent demand for KRAS mutation testing in the clinical setting to aid choice of therapy. The aim of this study was to evaluate six different… CONTINUE READING